Acquisitions1 Jan 2026, 11:55 am
Caplin Point Laboratories Acquires 10 ANDAs from Leading Multinational Generic Product Manufacturing Company
AI Summary
Caplin Point Laboratories Ltd, through its subsidiary companies of Caplin Steriles Limited and Caplin One Labs Limited, has acquired 10 approved ANDAs for Injectable and Opthalmic products from a leading Multinational Generic product manufacturing company. The addressable market for these products is $473.2 million for the 12-month period ending August 2025. The acquisition includes select oncology injectables which will be commercialized from a new dedicated oncology facility in Kakkalur. The company plans to extend these products to key non-U.S. markets, including Mexico, Canada, the European Union, and Brazil.
Key Highlights
- Caplin Point Laboratories acquires 10 ANDAs for Injectable and Opthalmic products from a leading Multinational Generic product manufacturing company.
- The addressable market for these products is $473.2 million for the 12-month period ending August 2025.
- The acquisition includes select oncology injectables which will be commercialized from a new dedicated oncology facility in Kakkalur.
- Caplin Point plans to extend these products to key non-U.S. markets, including Mexico, Canada, the European Union, and Brazil.
- Caplin Point has a unique business model catering predominantly to emerging markets of Latin America and Africa, and is known for its high-quality growth in cash flows, Profitability and Revenues over the last 15 years.